Themis Medicare, maker of diclofenac 1 ml injection, has been directed by the Food and Drug Administration authorities to stop manufacturing a key product. The company has been given an opportunity to be heard; it is taking necessary steps to reply suitably. The product is being manufactured and marketed by the company; it is also being supplied to a pharma company on principal to principal basis. The company has filed a petition in the Delhi High Court.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.